optic: ponatinib in resistant chronic-phase cml
Published 4 years ago • 273 plays • Length 4:19Download video MP4
Download video MP3
Similar videos
-
1:37
optic: ponatinib in chronic-phase cml
-
1:38
an update on the optic study: adjusting the dose of ponatinib for cp-cml
-
4:44
ponatinib in chronic-phase cml patients with prior second generation tki exposure
-
1:08
managing drug resistance in cp-cml with ponatinib and asciminib
-
1:40
using ponatinib to treat highly resistant chronic myeloid leukemia, results from a phase i trial
-
2:59
optic 3-year update: dose-optimization of 3 starting doses of ponatinib in cp-cml
-
2:20
dose modification of ponatinib in cp-cml: data from the pace and optic trials
-
1:43
dosing strategy of ponatinib in cp-cml: insights from the optic trial
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
1:46
ruxolitinib in 2024 and beyond: the good, the suboptimal, and the failure
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
1:17
ponatinib versus ascimininib in the third-line treatment of cml
-
1:35
safety of ponatinib in chronic-phase chronic myeloid leukemia (cml) patients
-
2:27
ascembl: asciminib versus bosutinib in third-line treatment of cp-cml
-
1:57
post-hoc analysis of optic: patient responses to ponatinib by t315i mutational status
-
1:35
long-term follow-up from the oiti trial: ponatinib in patients with cml in italy
-
1:35
optic post hoc analyses: optic and pace comparison & impact of mutations on ponatinib starting dose
-
1:29
what are the predictors of ponatinib treatment response?
-
0:52
rilzabrutinib: a novel promising btk inhibitor being explored in itp
-
1:18
celestial-tncll: ongoing phase iii study of sonrotoclax zanubrutinib vs ven obi for tn cll
-
3:31
ash 2021: new optic trial analysis shows ponatinib is effective in chronic myeloid leukemia patients
-
1:03
insights into the cartitude-6 trial: rationale and design